Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Cordis, Boston Scientific, Abbott Vascular Preferred Stent Brand Among Cardiologists According to New International Market Monitoring Service

February 15, 2012

Survey Reveals Most Cardiologists Would Use a Bioabsorbable Stent for Coronary Angioplasty According to iData Research

Vancouver, BC (PRWEB) February 15, 2012

According to a new market monitoring service from iData Research (http://www.idataresearch.net), the leading global authority in medical device market research, Cordis, Boston Scientific and Abbott Vascular were the preferred stent brands in the U.S., Europe, Middle East and Africa, while Medtronic had a strong market presence in Russia and Asia. The market monitoring survey also revealed that the majority of cardiologists in the U.S., Europe, Middle East and Africa would use a bioabsorbable stent for the treatment of coronary angioplasty. In contrast, the majority of cardiologists in Asia-Pacific would not use a bioabsorbable stent.

These results come from a comprehensive market monitoring service that tracks physician brand and product preferences, usage statistics and impressions and combines these with sales and procedure data on an ongoing basis. Hundreds of cardiologists were surveyed worldwide for bioabsorbable, bifurcated, drug-eluting and bare metal stents, stent-grafts, vulnerable plaque and deep vein thrombosis (DVT) treatment.

“The survey results revealed dramatic differences between geographical regions in usage trends,” says Dr. Kamran Zamanian, CEO of iData. “Cardiologists in the U.S. and Europe are more willing to use new technologies such as bifurcated and bioabsorbable stents, while Asia-Pacific and Latin American cardiologists are more resistant, citing the lack of long-term clinical data, early recoil and technical challenges as drawbacks to these technologies.”

The results indicated that drug-eluting stents have become the dominant stent type used in Europe. Their use is expected to continue to increase, with their market penetration growing from the base of almost 62% of the total stent market in 2010. In addition, interventional cardiologists, cardiac surgeons and general practitioners in the United States and Europe stated that drug therapies were the most effective treatment for deep vein thrombosis (DVT) citing their preferred brands, while vena cava interruption was a popular treatment option among Latin American physicians.

iData´s market monitoring service for global stent usage revealed trends on procedure volumes, stent brand choice, stent length and diameter preference, types of lesions and vessels stented, preferred stent delivery type and preferred drug coating. An accompanying market report states that the market for interventional cardiology is expected to exceed $4 billion by 2017, with increasing drug eluting stent sales as well as the emergence of bioabsorbable and bifurcated stents fueling market growth.

iData´s global cardiologist survey is a 4 report series and includes: “U.S. and International Vulnerable Plaque Treatment”, “Global Physician Survey: Stents by Brand, Length, Diameter, Type and Coating” and “International Deep Vein Thrombosis Treatment and Screening”. These surveys accompany iData´s global 3-report series on the “Markets for Interventional Cardiology Devices”.

For more information, register free on iData’s website at:

http://www.idataresearch.net/idata/registration.php

About iData Research

iData Research (http://www.idataresearch.net/idata/discoveridata.php) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: interventional cardiology, peripheral vascular, vascular access, cardiac surgery, orthopedics, dental, endoscopy and more.

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/2/prweb9194384.htm


Source: prweb